Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

Liver Failure Clinical Trial

Official title:

A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00608244
• Other study ID #: LCP Tacro 2012
• Status: Completed
• Phase: Phase 2
• First received: January 23, 2008
• Last updated: August 14, 2015
• Start date: November 2007
• Est. completion date: June 2008

Study information

• Verified date: August 2015
• Source: Veloxis Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.

Description:

A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.

Stable liver transplant patients who fulfill all I/E criteria will be enrolled and kept on Prograf for 7 days. Following a 24-hour PK study on Day 7 to determine pharmacokinetics for Prograf, all patients will be converted to once daily LCP-Tacro for 14 days with one fixed dose change allowed at Day 15.

On Day 14 and Day 21 a 24-hour LCP-Tacro PK study will be performed. On Day 22 patients will be converted back to their original twice daily dose of Prograf for a safety follow-up period of 30 days ending with a safety assessment on day 53.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: June 2008
• Est. primary completion date: June 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Men and women 18-65 years of age who are recipients of a liver transplant at least six months prior to enrollment

• Patients on oral Prograf therapy as part of their maintenance immunosuppression therapy, with stable doses and trough levels of tacrolimus of 5-12 ng/mL for at least four weeks prior to enrollment with at least two measurements at least two days apart in the screening period up to fourteen days prior to enrollment

• Concurrent immunosuppression with mycophenolate mofetil (MMF, CellCept) or mycophenolic acid delayed-release tablets (Myfortic) is allowed but patients on either of these medications should be on stable doses for at least four weeks prior to enrollment

• Patients with stable serum bilirubin, AST, ALT, and Alk Phos or GGT that are = 2 times the upper limit of normal based on local laboratory criteria

• Patients with serum creatinine =2.0 mg/dL prior to enrollment

• Able to swallow study medication

• Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study protocol.

• Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication and agree to use contraceptive measures to avoid pregnancy during participation in the trial.

Exclusion Criteria:

• Recipients of any transplanted organ other than a liver

• White blood cell count = 2.8 x 109/L

• Patients who are receiving a total dose of Prograf < 3 mg per 24 hours

• Patients who are receiving more than 10 mg of prednisone per day

• Patients unable or unwilling to provide informed consent

• Pregnant or nursing women

• Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception

• Administration of any other investigational agent in the three months prior to enrollment

• Patients receiving any drug interfering with tacrolimus metabolism

• Patients who have taken sirolimus within the three months prior to screening

• Patient with an episode of acute cellular requiring antibody therapy within the six months prior to enrollment

• Patients treated for acute cellular rejection within the thirty days prior to enrollment

• Patient who is HCV negative and has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver

• Patients presenting after liver transplantation with recurrent HCV infection, documented by presence of HCV RNA in serum and grade II or greater inflammation or stage II or greater fibrosis on liver biopsy

• Patients being actively treated with antiviral therapy, such as interferons or ribavirin, for recurrent hepatitis C.

• Patients with an alpha-feto protein = 20 ng/mL

• Patient has a current malignancy or a history of malignancy (within the past five years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully

• Patient has uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives

• Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus

• Patient will require therapy with any immunosuppressive agent other than those prescribed in the study

• Patient has a known hypersensitivity to corticosteroids or tacrolimus

• Patient has any form of current substance abuse (patients must pass a standard drug screen), psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator Version

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Liver Failure

Intervention

Drug:
• LCP Tacro
In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8. LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.
• Prograf
Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.

Locations

Country	Name	City	State
United States	University of Cincinnati	Cincinnati	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Veloxis Pharmaceuticals	CTI Clinical Trial and Consulting Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of Steady State Tacrolimus Trough Levels (C24).	Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.	7 Days	No
Primary	Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).	Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro.; The following time points were used to obtain the PK curve for Prograf on day 7: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 16, 20 and 24 hours after the morning dose.	7 Days	No
Primary	Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).	Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.	21 Days	No
Primary	Evaluation of Steady State Tacrolimus Exposure (AUC 0-24) on Day 21.	Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours).; The following time points were used to obtain the PK curve for LCP-Tacro on day 21: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20 and 24 hours post-dose.	21 Days	No
Primary	Safety Evaluation	A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.	52 days	Yes